To maximize the drugability potential, we target approaches to improve clinical benefits based on reverse translational science and emerging biology of the tumor microenvironment.
(Reverse)Translational Science
Identification of patients' unmet needs, novel targets, pathways, and mechanisms.
Drug Discovery & Development
Validation of target, mechanism of action, and proof of concept, and development of novel engager with high potency and good safety profile.
Immunotherapy
Boosting of anti-tumor immunity to fight against cancer.
Direct engagement of myeloid cells with target cells.
Activation of killing mechanism (such as phagocytosis) by myeloid cells directed towards target cells.
Stimulation of myeloid cells to release minimal cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment and enhance cytotoxic T cell function.
Cross presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.
REDWOOD CITY, Calif. & SHENZHEN, China – July 30, 2024 – LTZ Therapeutics, an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases. This round was led by new investor Lapam Capital and includes new investment participation from GL Ventures. In addition, the company has received continued investment from K2 Venture Partners and Shunwei Capital. The closing of this round brings LTZ’s total funding to approximately $50 million since the company was founded in 2022.
为了更好的呈现效果,移动端请竖屏浏览